SVF
Level D· Preclinical EvidenceLaboratory Study

Comprehensive arthroscopic management procedure and autologous microfragmented adipose tissue infiltration in mild-to-moderate glenohumeral osteoarthritis: two-year follow-up outcomes.

Giorgini A., Addala H., De Pasquale L., Micheloni GM., Fregni U., Porcellini G.

Laboratory Study with a reported sample of 19 on Osteoarthritis, Shoulder Pain, published in JSES Rev Rep Tech (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
JSES Rev Rep Tech (2026)
Country
Netherlands
Reported sample size
19
PMID
42389646
DOI
10.1016/j.xrrt.2026.100778

Abstract (original English)

The aim of this study was to evaluate clinical outcomes in patients with mild-to-moderate concentric glenohumeral osteoarthritis (GHOA) treated with arthroscopic surgery according to the Comprehensive Arthroscopic Management (CAM) procedure combined with intra-articular injection of autologous microfragmented adipose tissue (mFAT) (Lipogems). Since there was no CAM-only control group, the study does not assess the independent contribution of mFAT. In this retrospective study, 19 patients (mean age 52 years; 17 males, 2 females) with Samilson-Prieto grade 1-3 GHOA were included. All patients underwent arthroscopic CAM surgery followed by intra-articular injection of autologous mFAT. Primary outcomes were assessed using the visual analog scale for pain and the American Shoulder and Elbow Surgeons score at baseline (T 0 ) and at 1 (T 1 ), 3 (T 3 ), 6 (T 6 ), 12 (T 12 ), and 24 months (T 24 ) post-operatively. Significant improvements in both visual analog scale and American Shoulder and Elbow Surgeons scores were observed at 1 month and maintained up to 24 months ( P < .05). Patients aged ≤50 years or with grade 1-2 GHOA tended to experience greater clinical improvements. The observed improvements in pain and function exceeded published thresholds for the Minimal Clinically Important Difference and fell below the Patient Acceptable Symptom State, indicating that changes were not o

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence comes from animal or laboratory studies and has not been confirmed in humans.

How we grade evidence
ShoulderArm & ElbowOsteoarthritisShoulder Pain
View on PubMedDOI

Related research